Overview

Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an "in Vivo" Evaluation of the Molecular Effects on β-catenin Signaling Pathway.

Status:
Completed

Trial end date:
2016-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to obtain an "in vivo" confirmation that mesalazine induces the gene expression of μ-protocadherin and other related genes in the colon mucosa, as demonstrated in some "in vitro" experiments. .

Phase:

Phase 2

Details

Lead Sponsor:

SOFAR S.p.A.

Treatments:

Aminosalicylic Acid
Mesalamine